NovoCure (NVCR) Competitors

NovoCure (NASDAQ:NVCR) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Which has more volatility & risk, NVCR or GKOS?

NovoCure has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Is NVCR or GKOS more profitable?

Glaukos has a net margin of -21.43% compared to NovoCure's net margin of -27.13%. Glaukos' return on equity of -8.59% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-27.13%	-47.74%	-13.79%
Glaukos	-21.43%	-8.59%	-6.61%

Which has better earnings and valuation, NVCR or GKOS?

Glaukos has lower revenue, but higher earnings than NovoCure. Glaukos is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$605.22M	2.13	-$168.63M	-$1.56	-7.38
Glaukos	$383.48M	13.16	-$146.37M	-$1.65	-53.34

Do analysts rate NVCR or GKOS?

NovoCure presently has a consensus price target of $28.79, indicating a potential upside of 150.09%. Glaukos has a consensus price target of $127.42, indicating a potential upside of 44.78%. Given NovoCure's higher probable upside, research analysts clearly believe NovoCure is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Do institutionals and insiders hold more shares of NVCR or GKOS?

84.6% of NovoCure shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media prefer NVCR or GKOS?

In the previous week, Glaukos had 6 more articles in the media than NovoCure. MarketBeat recorded 11 mentions for Glaukos and 5 mentions for NovoCure. NovoCure's average media sentiment score of 0.74 beat Glaukos' score of 0.63 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Glaukos beats NovoCure on 12 of the 17 factors compared between the two stocks.